A new cancer treatment that links chemotherapy with an agent that homes in on specific breast cancer cells was significantly better than the current drug regimen at keeping patients' advanced tumors from progressing, according ...
Jun 3, 2012
0
0
Adding trastuzumab (trade name Herceptin) to the treatment offered to women who have HER2-positive breast cancer, significantly increases the chance of life being prolonged, and reduces the chance of tumours reappearing once ...
Apr 17, 2012
0
0
An international team of scientists, including four at Simon Fraser University, has made a discovery that will change the way the most deadly form of breast cancer is treated.
Apr 4, 2012
1
0
Because cases of Triple-Negative Breast Cancer (TNBC) are so genetically different, whole-genome sequencing is needed to detect the subtle molecular differences that might point to specific treatments for individual patients.
Apr 2, 2012
0
0
A new study has identified a key mechanism that causes breast cancer to spread. The research, published by Cell Press on March 30th in the journal Molecular Cell, enhances our knowledge about the signals that drive cancer ...
Mar 29, 2012
0
0
Breast cancers expressing the protein HER2 have a particularly poor prognosis. Treatment with trastuzumab (Herceptin) benefits some patients with HER2-positive breast cancer, but it is not as effective as had been hoped. ...
Feb 13, 2012
0
0
In patients with HER2-positive breast cancer, Tykerb (lapatinib) has been used both in combination with herceptin (trastuzumab) and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy treatment. ...
Jan 16, 2012
0
0
Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer ...
Dec 9, 2011
0
0
Initial results from an ongoing clinical trial, the first designed to examine the utility of whole-genome sequencing for triple negative breast cancer, were reported today during the CRTC-AACR San Antonio Breast Cancer Symposium.
Dec 8, 2011
0
0
One study presented at the meeting, which is being held in Budapest, Hungary, 7 to 10 December, reports on an initiative using echocardiography to document early warning signs of adverse effects from trastuzumab (Herceptin)¹, ...
Dec 7, 2011
0
0
